SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006230
Filing Date
2021-05-06
Accepted
2021-05-06 16:16:29
Documents
55
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20210331x10q.htm   iXBRL 10-Q 1055618
2 EX-31.1 adap-20210331xex31d1.htm EX-31.1 9819
3 EX-31.2 adap-20210331xex31d2.htm EX-31.2 10562
4 EX-32.1 adap-20210331xex32d1.htm EX-32.1 6129
5 EX-32.2 adap-20210331xex32d2.htm EX-32.2 6111
  Complete submission text file 0001558370-21-006230.txt   3992032

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20210331.xsd EX-101.SCH 29062
7 EX-101.CAL adap-20210331_cal.xml EX-101.CAL 40413
8 EX-101.DEF adap-20210331_def.xml EX-101.DEF 69317
9 EX-101.LAB adap-20210331_lab.xml EX-101.LAB 269783
10 EX-101.PRE adap-20210331_pre.xml EX-101.PRE 188412
11 EXTRACTED XBRL INSTANCE DOCUMENT adap-20210331x10q_htm.xml XML 627239
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 21898003
SIC: 2836 Biological Products, (No Diagnostic Substances)